Scientific Reports (May 2021)

Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India

  • Jaya Singh Kshatri,
  • Debdutta Bhattacharya,
  • Srikanta Kanungo,
  • Sidhartha Giri,
  • Subrata Kumar Palo,
  • Debaprasad Parai,
  • Jyotirmayee Turuk,
  • Asit Mansingh,
  • Hari Ram Choudhary,
  • Matrujyoti Pattnaik,
  • Girish Chandra Dash,
  • Prasantajyoti Mohanty,
  • Niranjan Mishra,
  • Durga Madhab Satapathy,
  • Sanjaya Kumar Sahoo,
  • Sanghamitra Pati,
  • ICMR-RMRC [OdiSHA-COVID-19] Serosurvey Team

DOI
https://doi.org/10.1038/s41598-021-89877-y
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 10

Abstract

Read online

Abstract This was a population based cross-sectional study carried out to estimate and compare the seroprevalence, hidden prevalence and determine the demographic risk factors associated with SARS-CoV-2 infection among adults in the three largest cities of Odisha, India, and ascertain the association with the progression of the epidemic. The survey carried out in August 2020 in the three largest cities of the state of Odisha, India. Blood samples were collected from the residents using random sampling methods and tested for anti- SARS CoV-2 antibodies using an automated CLIA platform. A total of 4146 participants from the 3 cities of Bhubaneswar (BBS), Berhampur (BAM) and Rourkela (RKL) participated. The female to male participation ratio was 5.9:10 across the three cities. The gender weighted seroprevalence across the three cities was 20.78% (95% CI 19.56–22.05%). While females reported a higher seroprevalence (22.8%) as compared to males (18.8%), there was no significant difference in seroprevalence across age groups. A majority of the seropositive participants were asymptomatic (90.49%). The case to infection ratio on the date of serosurvey was 1:6.6 in BBS, 1:61 in BAM and 1:29.8 in RKL. The study found a high seroprevalence against COVID-19 in urban Odisha as well as high numbers of asymptomatic infections. The epidemic curves had a correlation with the seroprevalence.